Plot­ting to go toe-to-toe with heavy­weight Pfiz­er, lit­tle Ei­dos plans quick score in PhI­II AT­TR-CM study

So how does a small cap biotech go toe-to-toe with the likes of Pfiz­er, when the phar­ma gi­ant is lin­ing up for one of the most care­ful­ly watched FDA de­ci­sions in bio­phar­ma?

Ei­dos Ther­a­peu­tics $EI­DX thinks it has the an­swer as they play David to Pfiz­er’s Go­liath.

The biotech to­day out­lined its piv­otal strat­e­gy for AG10, an oral small mol­e­cule de­signed to treat transthyretin amy­loid car­diomy­opa­thy, AT­TR-CM. Work­ing with the FDA, the biotech came up with a Phase III tri­al de­sign that the ex­ecs in charge say gives them two po­ten­tial piv­otal dead­lines. The first ar­rives af­ter 12 months of treat­ment, as pa­tients are giv­en a 6-minute walk test. The next comes af­ter 30 months, as re­searchers eval­u­ate pa­tient da­ta on all-cause mor­tal­i­ty and fre­quen­cy of car­dio­vas­cu­lar-re­lat­ed hos­pi­tal­iza­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER